TY - JOUR
T1 - HPV testing versus p16 immunohistochemistry in oropharyngeal squamous cell carcinoma
T2 - results from the DAHANCA 19 study
AU - Lilja-Fischer, Jacob Kinggaard
AU - Kristensen, Morten Horsholt
AU - Lassen, Pernille
AU - Steiniche, Torben
AU - Tramm, Trine
AU - Stougaard, Magnus
AU - Maare, Christian
AU - Johansen, Jørgen
AU - Primdahl, Hanne
AU - Kristensen, Claus Andrup
AU - Andersen, Maria
AU - Eriksen, Jesper Grau
AU - Overgaard, Jens
PY - 2023/11
Y1 - 2023/11
N2 - INTRODUCTION: The prognosis after primary (chemo-)radiotherapy for oropharyngeal squamous cell carcinoma (OPSCC) is affected by Human Papillomavirus (HPV) status, with a better prognosis in HPV-positive OPSCC. HPV-status is routinely assessed by p16 immunohistochemistry (IHC), but additional HPV DNA testing is debated. Also, there are numerous HPV genotypes, which prognostic role may need clarification. The purpose of this study was: (1) to test a custom-made targeted HPV next generation sequencing (NGS) panel in OPSCC, (2) to determine correlation with p16 IHC, and (3) to assess the impact of HPV DNA testing on outcome in the prospectively randomized clinical trial DAHANCA 19.MATERIALS AND METHODS: We included 271 patients with OPSCC treated with primary (chemo-)radiotherapy in the DAHANCA 19 trial. Of these, 199 (73%) were p16-positive. HPV-status was determined by targeted HPV next generation sequencing (NGS), using a custom-made HPV genotyping panel.RESULTS: HPV was detected in 194 tumor samples. p16 IHC and NGS HPV status were concordant in 265 (98%) of 271 patients, whereas we did not detect HPV DNA in 5 p16-positive tumors. HPV16 accounted for 169 of 194 HPV-positive cases (87%). HPV genotypes 18, 31, 33, 35, and 59 were also detected.Loco-regional failure and overall survival were similar whether patients were separated by p16 IHC, or HPV DNA status (p < 0.0001 for all) and did not depend on HPV genotype (p = 0.9 and p = 0.7).CONCLUSION: In the present study, HPV DNA testing or typing in a Danish OPSCC cohort did not add additional information to p16 IHC, the most widely used and accepted prognostic indicator.
AB - INTRODUCTION: The prognosis after primary (chemo-)radiotherapy for oropharyngeal squamous cell carcinoma (OPSCC) is affected by Human Papillomavirus (HPV) status, with a better prognosis in HPV-positive OPSCC. HPV-status is routinely assessed by p16 immunohistochemistry (IHC), but additional HPV DNA testing is debated. Also, there are numerous HPV genotypes, which prognostic role may need clarification. The purpose of this study was: (1) to test a custom-made targeted HPV next generation sequencing (NGS) panel in OPSCC, (2) to determine correlation with p16 IHC, and (3) to assess the impact of HPV DNA testing on outcome in the prospectively randomized clinical trial DAHANCA 19.MATERIALS AND METHODS: We included 271 patients with OPSCC treated with primary (chemo-)radiotherapy in the DAHANCA 19 trial. Of these, 199 (73%) were p16-positive. HPV-status was determined by targeted HPV next generation sequencing (NGS), using a custom-made HPV genotyping panel.RESULTS: HPV was detected in 194 tumor samples. p16 IHC and NGS HPV status were concordant in 265 (98%) of 271 patients, whereas we did not detect HPV DNA in 5 p16-positive tumors. HPV16 accounted for 169 of 194 HPV-positive cases (87%). HPV genotypes 18, 31, 33, 35, and 59 were also detected.Loco-regional failure and overall survival were similar whether patients were separated by p16 IHC, or HPV DNA status (p < 0.0001 for all) and did not depend on HPV genotype (p = 0.9 and p = 0.7).CONCLUSION: In the present study, HPV DNA testing or typing in a Danish OPSCC cohort did not add additional information to p16 IHC, the most widely used and accepted prognostic indicator.
KW - Humans
KW - Squamous Cell Carcinoma of Head and Neck
KW - Oropharyngeal Neoplasms/pathology
KW - Carcinoma, Squamous Cell/pathology
KW - Papillomavirus Infections
KW - Immunohistochemistry
KW - Prognosis
KW - Human Papillomavirus Viruses
KW - Head and Neck Neoplasms
KW - DNA
KW - Cyclin-Dependent Kinase Inhibitor p16
UR - http://www.scopus.com/inward/record.url?scp=85174213318&partnerID=8YFLogxK
U2 - 10.1080/0284186X.2023.2266127
DO - 10.1080/0284186X.2023.2266127
M3 - Journal article
C2 - 37837201
SN - 0284-186X
VL - 62
SP - 1384
EP - 1388
JO - Acta Oncologica
JF - Acta Oncologica
IS - 11
ER -